• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Slowing Cancer Is Not Enough: FDA Rejects Ivonescimab Without Proof It Extends Lives

Naresh Nunna by Naresh Nunna
34 minutes ago
in Science News
0
Illustration of a two-armed antibody binding an immune cell receptor

A bispecific antibody binds two targets at once. The FDA declined to approve ivonescimab for EGFR-mutant lung cancer because its trial did not show a statistically significant survival benefit. (Illustration)

The US Food and Drug Administration has declined to approve ivonescimab, a first-of-its-kind antibody that blocks both the PD-1 immune checkpoint and the blood-vessel growth factor VEGF, for patients with EGFR-mutant lung cancer whose disease has progressed after targeted therapy. In its pivotal trial, the drug added to chemotherapy cut the risk of disease progression by 48%. But it did not produce a statistically significant improvement in overall survival, and the FDA said that was not enough. The decision, disclosed by Summit Therapeutics on 15 November, is the first US regulatory verdict on a closely watched class of cancer drugs.

In cancer medicine, two measures dominate the evaluation of new treatments: how long patients live without their disease getting worse (progression-free survival, PFS) and how long they live (overall survival, OS). Drugs are often approved on PFS when the evidence is strong and the treatment is not unduly toxic. The FDA’s decision on ivonescimab shows where that latitude ends.

What happened

Summit Therapeutics, which holds rights to ivonescimab in the United States, Europe and several other markets, said on Sunday that it had received a complete response letter from the FDA. This is the agency’s formal notice that an application cannot be approved in its current form. The decision date had been 14 November.

According to Summit’s account of the letter, the FDA concluded that “substantial evidence of effectiveness is not established” without a statistically significant improvement in overall survival, and that PFS alone did not support a positive balance of benefit and risk in this setting. Summit’s release cites no safety, manufacturing or data-integrity problem. The FDA does not publish complete response letters, so its reasoning is known only as the company reports it.

The application covered ivonescimab with platinum-based chemotherapy for adults with EGFR-mutated, non-squamous non-small cell lung cancer (NSCLC) whose disease had progressed after an EGFR tyrosine kinase inhibitor.

The trial behind the decision

The application rested on HARMONi, a Phase III trial in 438 patients. Ivonescimab plus chemotherapy was compared with chemotherapy alone, and the results reported by Summit and Reuters are as follows:

  • Progression-free survival: the primary endpoint was met. Median PFS was 6.8 months with ivonescimab against 4.4 months with chemotherapy alone, a hazard ratio of 0.52, meaning a 48% lower risk of progression.
  • Overall survival (primary analysis): 16.8 months against 14.0 months, a hazard ratio of 0.79. The p-value of 0.057 narrowly missed the conventional threshold for statistical significance.
  • Overall survival (longer follow-up): Summit says it showed a hazard ratio of 0.76, consistent in Asian and Western patients. This was a post hoc analysis, not the pre-specified test.
  • Safety: treatment-related adverse events led to discontinuation in 7.3% of patients on ivonescimab and 5.0% on chemotherapy alone. Treatment-related deaths were 1.8% and 2.3% respectively.

Why survival mattered here

The FDA’s position reflects a recurring concern. Adding a drug to chemotherapy adds cost and side-effects, so regulators want to know that patients gain something they value. A delay in tumour growth on scans does not always translate into longer life. In later-line lung cancer, after targeted therapy has failed, the agency evidently judged that a survival benefit had to be demonstrated, not inferred.

Post hoc analyses, however encouraging, cannot replace a pre-specified result, because looking again at accumulating data raises the chance of finding a favourable result by chance. A survival trend that falls just short of significance is therefore suggestive, not conclusive.

The FDA does have a route for approving drugs on early or surrogate evidence. Its accelerated-approval pathway allows conditional approval on endpoints “reasonably likely” to predict clinical benefit, provided confirmatory trials follow. That pathway, however, is intended mainly for conditions with unmet need, and it has come under growing scrutiny after several cancer approvals were later withdrawn when confirmatory trials failed to show benefit. For a regimen that adds a new drug to established chemotherapy, the agency appears to have set a higher bar. (This description of FDA pathways is general regulatory context, not drawn from the letter itself.)

What makes ivonescimab different

Most immunotherapies for lung cancer block a single target, PD-1 or its partner PD-L1, releasing a brake on the immune system. Ivonescimab is a bispecific antibody: a single molecule that also blocks VEGF, a signal tumours use to grow new blood vessels. Combining the two in one molecule is intended to concentrate both effects in the tumour.

The drug was developed by Akeso in China, where regulators approved it for this indication in May 2024. Summit licensed it in 2022 in a deal reported by Reuters to be worth up to US$5 billion. Reuters also reports that AstraZeneca said in September it would invest US$2 billion in Summit, an indication of how much commercial weight rests on the molecule. Many companies are now developing PD-1/VEGF bispecifics, so the FDA’s first decision on the class is being closely studied.

What it does and does not mean

The rejection applies to one indication, based on one trial. It is not a judgement that the drug class does not work. Summit says ivonescimab is being tested in other settings, including first-line lung cancer in the HARMONi-3 trial, colorectal and urothelial cancers, and in combinations with partners’ drugs. Summit has not said whether it will seek a meeting with the FDA or resubmit with more mature survival data.

The India angle

EGFR mutations are considerably more common in lung cancers among Asian patients, including Indians, than among patients of European descent. Patients whose disease progresses after targeted therapy have limited options. The FDA’s reasoning is relevant to India’s oncologists and to the Central Drugs Standard Control Organisation, which often considers drugs already approved, or rejected, elsewhere. NSH found no Indian filing for ivonescimab. The figure on EGFR prevalence is a general characterisation and should be sourced to Indian data before publication.

What to watch

  • Whether Summit requests a Type A meeting or plans a resubmission.
  • First-line results from HARMONi-3.
  • Regulatory decisions on competing PD-1/VEGF bispecifics.

– Sai Chaitanya Puligadda

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: DrugRegulationFDAHealthSciencesImmunotherapyLungCanceroncologypharmaceuticals
Naresh Nunna

Naresh Nunna

Other Posts

Airliner without livery under inspection in a maintenance hangar at dawn

India’s Air-Safety Regulator Under the Microscope: FAA Audit Begins With Category 1 Status at Stake

November 19, 2026
2
Satellite view of a tropical cyclone forming over the ocean

Akvan Gathers Strength: Depression Expected to Become a Cyclone Today as North Andhra Faces Its Third Storm Threat in a Month

November 19, 2026
3

24 Lakh New Cases Found: Andhra Pradesh’s Mass Screening Exposes the Hidden Scale of Hypertension and Diabetes

Surgery Before Birth: AIIMS Delhi Performs India’s First Open Foetal Repair of Severe Spina Bifida

When the Grid Blinks: Inside the Wave of Global Outages and AI-Driven Cyberattacks

The Science of Smart Warmth: Inside the Modern Electric Blanket

Sai Parenterals Strengthens Presence with Majority Stake Acquisition in Bian Therapeutics

Lifting the Crop Off the Floor: Why Raised Beds Are Gaining Ground in a Water-Short Country

Please login to join discussion

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
9

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist